Lv4
550 积分 2024-11-19 加入
Navigating the clinical progress of antibody-drug conjugates: Emerging opportunities and remaining challenges
12小时前
已关闭
Paclitaxel in colon cancer management: from conventional chemotherapy to advanced nanocarrier delivery systems
4天前
已完结
Ethics of Backfilling in Early-Phase Oncology Trials
7天前
已完结
Comprehensive management strategies for amivantamab-induced toxicities and review of the literature
7天前
已完结
Re-Evaluating Antibody–Drug Conjugate Linker Stability: Assessment, Interpretation, and Clinical Translation
16天前
已完结
Beyond EGFR inhibition in head and neck squamous cell carcinoma: Overcoming resistance mechanisms and novel therapeutic frontiers
22天前
已完结
Emerging EGFR-Targeted Therapy in Head and Neck Cancer
24天前
已完结
Concurrent tumor lysis syndrome and 5-fluorouracil encephalopathy during the first cycle of zolbetuximab plus mFOLFOX6 for CLDN18.2-positive gastric cancer: a case report
3个月前
已完结
BL-B01D1, a first-in-class EGFR–HER3 bispecific antibody–drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study
3个月前
已完结
A bispecific antibody–drug conjugate targeting EGFR and HER3 in metastatic esophageal squamous cell carcinoma: a phase 1b trial
3个月前
已完结
皖公网安备34019202002308
